AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
fallback

Auctimet VG 1mg/500mg/0.2mg Tablet SR

Prescription Icon
Prescription Required

Marketer

Bioaltus Pharmaceuticals Pvt Ltd

Salt Composition

Glimepiride (1mg) + Metformin (500mg) + Voglibose (0.2mg)

Overview Auctimet VG 1mg/500mg/0.2mg Tablet SR

Diabetease Trio 1mg/500mg/0.2mg Extended-Release Tablets are classified as antidiabetic medications. This triple-combination therapy is indicated for adult patients with type 2 diabetes mellitus to manage blood glucose control. Administer this medication with food, consistently at the same time daily for optimal efficacy. Dosage will be determined and adjusted by your physician based on your blood sugar response. Continue taking this medicine as prescribed, even with controlled blood sugar or feeling well. Discontinuing treatment without consulting your doctor can lead to elevated blood glucose, increasing the risk of kidney complications, vision loss, neuropathy, and limb amputation. This medication is only one component of a comprehensive diabetes management plan, including dietary modifications, regular exercise, and weight management as recommended by your healthcare provider. Lifestyle choices significantly impact diabetes control. Hypoglycemia (low blood sugar) is the most common adverse effect of Diabetease Trio 1mg/500mg/0.2mg Extended-Release Tablets. Learn to recognize symptoms like sweating, dizziness, headache, and tremors, and know how to treat them. Regular meals and carrying a fast-acting glucose source (e.g., sugary foods, fruit juice) are crucial preventative measures. Alcohol consumption should be minimized due to its potential to exacerbate hypoglycemia. Other possible side effects include altered taste, nausea, diarrhea, abdominal pain, headache, edema, blurred vision, fractures, and upper respiratory infections. Weight gain may occur. This medication is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, or severe hepatic or renal impairment. Inform your doctor of any history of heart disease before initiating treatment; it may not be appropriate for all individuals. Pregnant or breastfeeding individuals should seek medical advice prior to use. Regular blood glucose monitoring, along with periodic blood tests to assess blood cell counts and liver function, may be recommended by your physician.

Uses of Auctimet VG 1mg/500mg/0.2mg Tablet SR

Managing type 2 diabetes

Major Benefits of Auctimet VG 1mg/500mg/0.2mg Tablet SR:

Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. Ingest the Auctimet VG 1mg/500mg/0.2mg Tablet SR whole; do not break, crush, or chew it. Administer on an empty stomach.

Common Side effects of Auctimet VG 1mg/500mg/0.2mg Tablet SR:

  • Nausea
  • Diarrhea
  • Abdominal pain
  • Hypoglycemia (low blood glucose level)
  • Loss of appetite

How to use Auctimet VG 1mg/500mg/0.2mg Tablet SR:

Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. Ingest the Auctimet VG 1mg/500mg/0.2mg Tablet SR whole; do not alter its form by chewing, crushing, or breaking. Administer on an empty stomach.

How Auctimet VG 1mg/500mg/0.2mg Tablet SR works:

The extended-release tablet, Auctimet VG, contains a triple-action formulation of antidiabetic agents at doses of 1mg, 500mg, and 0.2mg.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Combining alcohol and Auctimet VG 1mg/500mg/0.2mg SR tablets poses a safety risk.

PregnancyPregnancyCONSULT YOUR DOCTOR

The extended-release Auctimet VG 1mg/500mg/0.2mg tablet may pose risks during pregnancy. While human data is scarce, animal research indicates potential harm to a fetus. A physician will assess the advantages against possible risks prior to prescribing this medication. Seek medical advice before use.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

Prolonged-release Auctimet VG 1mg/500mg/0.2mg tablets are likely unsuitable for breastfeeding mothers. Available human data indicate potential transfer to breast milk, posing a risk to the infant.

DrivingDrivingCAUTION

Driving ability can be impaired by both hypoglycemia and hyperglycemia. Refrain from driving if you experience these conditions.

KidneyKidneyUNSAFE

Patients with kidney disease should likely avoid Auctimet VG 1mg/500mg/0.2mg Tablet SR, as its use may be unsafe. Medical advice is recommended. Furthermore, its use is discouraged in individuals with severe kidney impairment.

LiverLiverCAUTION

Exercise caution when administering Auctimet VG 1mg/500mg/0.2mg Tablet SR to individuals with hepatic impairment; dosage modification may be necessary. Consult a physician before use. For patients experiencing mild to moderate liver dysfunction, initiate treatment with a reduced Auctimet VG 1mg/500mg/0.2mg Tablet SR dosage; its use is contraindicated in cases of severe liver disease.

What if you forget to take Auctimet VG 1mg/500mg/0.2mg Tablet SR :

Should you forget a dose of Auctimet VG 1mg/500mg/0.2mg Tablet SR, administer it at your earliest convenience. If, however, your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.

Facts to Know About Auctimet VG 1mg/500mg/0.2mg Tablet SR

LabelValue
Potential for Dependence None.
Type of Treatment Medication for diabetes

FAQs on Auctimet VG 1mg/500mg/0.2mg Tablet SR

Auctimet VG 1mg/500mg/0.2mg Extended-Release tablets contain glimepiride, metformin, and voglibose. This triple-drug formulation manages type 2 diabetes mellitus by regulating blood glucose in adults, when coupled with a healthy diet and regular physical activity. Glimepiride stimulates insulin secretion from the pancreas, thereby reducing blood sugar. Metformin reduces hepatic glucose production and enhances insulin responsiveness. Voglibose, an alpha-glucosidase inhibitor, decreases post-meal blood glucose. This medication is unsuitable for treating type 1 diabetes mellitus.
Patients taking Auctimet VG 1mg/500mg/0.2mg SR tablets may experience common adverse reactions including hypoglycemia, nausea, diarrhea, altered taste perception, flatulence, abdominal pain, headache, skin eruptions, and respiratory infections.
Patients with hypersensitivity to Auctimet VG 1mg/500mg/0.2mg Tablet SR constituents or inactive ingredients should not use this medication. Its administration is contraindicated in individuals with moderate to severe renal impairment, inflammatory bowel disease, colonic ulcers, and underlying metabolic acidosis, such as diabetic ketoacidosis.
Combining Auctimet VG 1mg/500mg/0.2mg SR tablets with alcohol is unsafe. This combination could lead to dangerously low blood sugar (hypoglycemia) and raise the risk of lactic acidosis.
Indeed, Auctimet VG 1mg/500mg/0.2mg Tablet SR may induce hypoglycemia. Low blood sugar can manifest as nausea, headache, irritability, hunger pangs, sweating, lightheadedness, tachycardia, and feelings of anxiety or tremor. The risk increases with skipped or delayed meals, alcohol consumption, excessive physical activity, or concomitant use of other antidiabetic medications. Consequently, consistent blood glucose monitoring is crucial. Carrying readily available glucose sources, such as glucose tablets, honey, or fruit juice, is advisable.
Retain this medication within its original, sealed packaging. Follow the storage guidelines specified on the product's packaging or label. Discard any remaining medicine. Ensure it remains inaccessible to children, animals, and others.
Auctimet VG 1mg/500mg/0.2...
72
MRP 88
18% off